Roflumilast Foam: Four ARRECTOR Checks

If a prescription foam coats your hair but misses the affected skin, ask for an application demonstration. AAD¹ scalp-psoriasis guidance advises moving hair aside so medicine reaches the scalp. Also tell the dermatologist if itch is unbearable; scratching can worsen psoriasis, cause bleeding and contribute to hair loss.¹

Selection

ARRECTOR randomized 432 people aged 12+ with at least moderate scalp and mild body plaque psoriasis to daily 0.3% roflumilast foam or vehicle for eight weeks. Vehicle contained no drug.²

Two outcomes

Week-eight success estimates, foam versus vehicle, were 66.4% versus 27.8% on the scalp and 45.5% versus 20.1% on the body. Success required clear/almost-clear plus at least two grades of improvement. Initially mild body disease therefore required clear. Both comparisons favored foam (P < .001).²

Missing ratings

376 completed; all 432 were analyzed. Missing ratings were estimated. A post-unblinding analysis revision counted stopping for adverse effects or ineffectiveness as failure.²³

Adverse events affected 75/281 versus 25/151. Arcutis funded and analyzed the trial; authors disclosed company ties. Eight weeks cannot establish long-term effectiveness or superiority to active treatments.²

Prescription checks

Check that the prescription says 0.3% foam and that the diagnosis is psoriasis. The same foam also has a seborrheic dermatitis indication, but that condition has separate trials. Other roflumilast formulations have different labels.⁴

The current US foam label specifies once-daily application to affected skin or scalp that is not wet. Shake the can, rub the thin layer in completely and wash your hands afterward. Keep it out of the eyes, mouth and vagina.⁴

Moderate or severe liver impairment is a contraindication. The foam is flammable: avoid fire, flame and smoking during and immediately after application. Ask a pharmacist to review all medicines, including contraceptives, because certain combinations increase roflumilast exposure.⁴

Discuss pregnancy and breastfeeding before use; human pregnancy data are insufficient. The label advises avoiding use during labor and delivery. During breastfeeding, avoid the nipple and areola and prevent infant contact with treated skin.⁴

For scale that interferes with application, ask your dermatologist whether a scale softener belongs in the plan. AAD¹ advises gentle washing and scale removal; picking can provoke a flare. Bring the product names and ask how their application schedules fit together.¹

“Describe It Before You Sort It” in Skin, Head to Toe organizes location, appearance and sensation, timing and other body changes. Use those observations to describe which scalp and body areas remain troublesome at review.